Inclusion Criteria:

          -  Subjects must satisfy the following criteria to be enrolled in the study:

               1. Adults (age ≥ 18 years at the time of signing the ICD) with documented diagnosis
                  of MM and measurable disease (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200
                  mg/24 hours).

               2. Subjects enrolling in Cohort A (POM+LD-dex) must have received 2 prior treatment
                  lines of anti-myeloma therapy. Subjects enrolling in Cohort B and Cohort C
                  (POM+DARA+LD-dex) must have received 1 or 2 prior treatment lines of anti-myeloma
                  therapy.

               3. All subjects must have received prior treatment with LEN or a LEN-containing
                  regimen for at least 2 consecutive cycles as the most recent treatment regimen.

               4. All subjects must have documented disease progression during or after their last
                  antimyeloma therapy.

               5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance
                  status score of 0, 1, or 2.

               6. Subjects must understand and voluntarily sign an ICD prior to any study related
                  assessments/procedures being conducted.

               7. Subjects must be able to adhere to the study visit schedule and other protocol
                  requirements.

               8. All subjects must provide an adequate bone marrow sample at screening that
                  definitively evaluates the presence or absence of myelodysplastic changes.

               9. Females with child-bearing potential (FCBP†) must agree to use 2 reliable forms
                  of contraception* simultaneously or practice complete abstinence from
                  heterosexual contact for at least 28 days before starting study drug, while
                  participating in the study (including during dose interruptions), and for at
                  least 28 days after study treatment discontinuation and must agree to regular
                  pregnancy testing during this timeframe. For subjects enrolled in Cohort B and
                  Cohort C, pregnancy prevention and testing will continue until 3 months after
                  last dose of daratumumab.

              10. Females must agree to abstain from breastfeeding during study participation and
                  28 days after study drug discontinuation. Female subjects enrolled in Cohort B
                  and Cohort C must agree to abstain from breastfeeding and donating eggs during
                  study participation and until 3 months after last dose of daratumumab.

              11. Males must agree to use a latex condom during any sexual contact with FCBP while
                  participating in the study and for 28 days following discontinuation from this
                  study, even if he has undergone a successful vasectomy. Male subjects enrolled in
                  Cohort B and Cohort C must agree to use a latex condom during any sexual contact
                  with FCBP while participating in the study and until 3 months after last dose of
                  daratumumab.

              12. Males must also agree to refrain from donating semen or sperm during the
                  treatment phase and for 28 days after discontinuation from this study treatment.
                  Male subjects enrolled in Cohort B and Cohort C must also agree to refrain from
                  donating semen or sperm during the treatment phase and until 3 months after last
                  dose of daratumumab.

              13. All subjects must agree to refrain from donating blood while on study therapy and
                  for 28 days after discontinuation from this study treatment.

              14. All subjects must agree not to share medication.

                  Exclusion Criteria:

                  The presence of any of the following will exclude a subject from study
                  enrollment:

               1. Any of the following laboratory abnormalities:

                  • Absolute neutrophil count < 1,000/μL

                  • Platelet count < 75,000/μL for subjects in whom < 50% of bone marrow nucleated
                  cells are plasma cells; or a platelet count < 30,000/μL for subjects in whom ≥
                  50% of bone marrow nucleated cells are plasma cells.

                  • Severe renal impairment (Creatinine Clearance [CrCl] < 30 mL/min) requiring
                  dialysis.

                    -  Corrected serum calcium > 11.5 mg/dL (> 2.8 mmol/L)

                    -  Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior red blood cell transfusion or
                       recombinant human erythropoietin use is permitted)

                    -  Serum SGOT/AST or SGPT/ALT > 3.0 x the upper limit of normal (ULN)

                    -  Serum total bilirubin > 2.0 mg/dL (34.2 μmol/L); or > 3.0 x ULN for subjects
                       with hereditary benign hyperbilirubinemia

               2. Prior history of malignancies, other than MM, unless the subject has been free of
                  the disease for more than 5 years. Allowed exceptions include the following:

                  •Basal or squamous cell carcinoma of the skin

                  •Carcinoma in situ of the cervix or breast

                  • Incidental histological finding of prostate cancer (TNM [tumor, nodes,
                  metastasis] stage of T1a or T1b)

               3. Previous therapy with pomalidomide or daratumumab

               4. Hypersensitivity to thalidomide, LEN, or dex (this includes ≥ Grade 3 rash during
                  prior thalidomide or LEN therapy)

               5. Subjects who received an allogeneic bone marrow or allogeneic peripheral blood
                  stem cell transplant less than 12 months prior to initiation of study treatment
                  and who have not discontinued immunosuppressive treatment for at least 4 weeks
                  prior to initiation of study treatment and are currently dependent on such
                  treatment.

               6. Subjects with any one of the following:

                  • Congestive heart failure (NY Heart Association Class III or IV)

                    -  Myocardial infarction within 12 months prior to starting study treatment

                    -  Unstable or poorly controlled angina pectoris, including Prinzmetal's
                       variant angina pectoris

               7. Subjects who received any of the following within 14 days of initiation of study
                  treatment:

                  • Major surgery (kyphoplasty is not considered major surgery)

                  • Use of any anti-myeloma drug therapy

               8. Use of any investigational agents including for the treatment of multiple myeloma
                  within 28 days or 5 half-lives (whichever is longer) of treatment, unless
                  approved by the sponsor.

               9. Incidence of gastrointestinal disease that may significantly alter the oral
                  absorption of Pomalidomide.

              10. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment

              11. Any serious medical condition, laboratory abnormality, or psychiatric illness,
                  that would preclude participation in the study, or interfere with interpretation
                  of the study results

              12. Pregnant or breastfeeding females

              13. Known human immunodeficiency virus (HIV) positivity; active infectious hepatitis
                  A, B, or C; or chronic hepatitis B or C

                  All subjects will be tested for hepatitis B surface antigen (HBsAg), hepatitis B
                  surface antibody (antiHBs), and hepatitis B core antibody (antiHBc). Subjects
                  with the following serological testing are considered not eligible:

                    -  HBsAg positive

                    -  HBsAg negative, anti-HBs positive and/or anti-HBc positive and detectable
                       viral DNA

                  Note:

                    -  Subjects who are HBsAg negative, anti-HBs positive, and/or anti-HBc
                       positive, viral DNA negative are eligible. For these subjects, DNA
                       monitoring and prophylactic medication for HBV reactivation are recommended
                       per local practice.

                    -  Subjects who are seropositive because of hepatitis B virus vaccination are
                       eligible (anti-HBs positive, anti-HBc negative, and HBsAg negative).

                  All subjects will be tested for hepatitis C antibody. Subjects are not eligible
                  if known seropositive for hepatitis C virus.

                  Note:

                  • Subjects who are hepatitis C antibody positive but show no detectable viral RNA
                  for 6 months prior to initiation of study treatment are eligible.

              14. For subjects enrolling in Cohort B and Cohort C - Subject has known allergies,
                  hypersensitivity to mannitol, corticosteroids, monoclonal antibodies or human
                  proteins, or their excipients (refer to the Daratumumab IB), or known sensitivity
                  to mammalian-derived products.